| Net Cash Provided by (Used in) Operating Activities |
$7,729,236 |
USD |
|
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$3,630,772 |
USD |
-258% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
100,000,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
3,037,709 |
shares |
15% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0.1 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$4,098,464 |
USD |
|
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$9,490,747 |
USD |
183% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Valuation Allowance |
$363,533 |
USD |
177% |
Q3 2025 |
Q3 2025 |
| Deferred Income Tax Expense (Benefit) |
$2,725 |
USD |
90% |
Q1 2025 |
Q1 2025 |
| Preferred Stock, Shares Authorized |
500,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Depreciation, Depletion and Amortization |
$6,250 |
USD |
0% |
Q1 2025 |
Q1 2025 |
| Preferred Stock, Par or Stated Value Per Share |
10 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |